BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Bolt Biotherapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$4.04+0.04 (+1.00%)

Close on Oct 19, 2026

Market cap: $6.83M
P/E (TTM): –
Dividend yield: –

Bolt Biotherapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	7.70	7.69	7.88	5.73	1.26	0.23
Research & Development	29	57	62	73	76	40
General & Administrative	14	18	23	23	18	9.06
Operating Expenses	44	81	84	96	94	49
Operating Income	-36	-73	-76	-90	-93	-49
Other Non-Operating Income	2.74	9.93	7.00	2.22	-5.80	-12
Merger & Restructuring Charges	1.48	3.34	0	–	–	–
Asset Impairment Charges	0	1.47	0	0	0	0
Gain (Loss) on Sale of Assets	0.29	0.07	0	–	-0.11	–
Pretax Income	-33	-63	–	–	–	–
Income Tax Expense	0	0	0	0	0	0
Net Income incl. Noncontrolling Interests	-33	-63	-69	-88	-99	-61
Net Income	-33	-63	-69	-88	-99	-61
EPS (Basic)(per share)	-17.85	-33.06	-36.60	-47.20	-59.40	-577.80
EPS (Diluted)(per share)	-17.85	-33.06	-36.60	-47.20	-59.40	-577.80
Shares Outstanding (Basic, Weighted)(shares)	1.87	1.91	1.89	1.87	1.66	0.10
Shares Outstanding (Diluted, Weighted)(shares)	1.87	1.91	1.89	1.87	1.66	0.11
EBITDA	-35	-71	-74	-89	-92	-49

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -654.5%
Net margin: -611.5%
Return on equity, FY2025: -79.7%

Financial strength

Current ratio: 2.61
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 163.5%

Valuation

P/E ratio: –
Price to sales: 1.45
Price to book: 0.54
Dividend yield: –